{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:37:35Z","timestamp":1793637455410,"version":"4.5.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100833"],"award-info":[{"award-number":["82100833"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U21A20355"],"award-info":[{"award-number":["U21A20355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Medical Research Project of Chongqing Science and Technology Commission & Chongqing Health and Family Planning Commission","award":["Major Project, 2022ZDXM003"],"award-info":[{"award-number":["Major Project, 2022ZDXM003"]}]},{"name":"National key research & development plan of China, major project of prevention and treatment for common diseases","award":["2021YFC2501600, sub-project: 2021YFC2501603"],"award-info":[{"award-number":["2021YFC2501600, sub-project: 2021YFC2501603"]}]},{"name":"The National Key Research and Development Project","award":["2022YFC2505300, sub-project 2022YFC2505301"],"award-info":[{"award-number":["2022YFC2505300, sub-project 2022YFC2505301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03520-6","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:01:35Z","timestamp":1696496495000},"page":"178-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Screening for primary aldosteronism on and off interfering medications"],"prefix":"10.1007","volume":"83","author":[{"given":"Xiaoyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aipin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-6445","authenticated-orcid":false,"given":"Qifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Chongqing Primary Aldosteronism Study (CONPASS) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangla","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"3520_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69, 1811\u20131820 (2017). https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052","journal-title":"J. Am. Coll. Cardiol."},{"key":"3520_CR2","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC K\u00e4yser","year":"2016","unstructured":"S.C. K\u00e4yser, T. Dekkers, H.J. Groenewoud, G.J. van der Wilt, J. Carel Bakx, M.C. van der Wel et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J. Clin. Endocrinol. Metab. 101, 2826\u201335 (2016). https:\/\/doi.org\/10.1210\/jc.2016-1472","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3520_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D'ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018). https:\/\/doi.org\/10.1016\/s2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3520_CR4","doi-asserted-by":"publisher","first-page":"147032032110037","DOI":"10.1177\/14703203211003781","volume":"22","author":"Y Jing","year":"2021","unstructured":"Y. Jing, K. Liao, R. Li, S. Yang, Y. Song, W. He et al. Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: a Meta-analysis. J. Renin Angiotensin Aldosterone Syst. 22, 14703203211003781 (2021). https:\/\/doi.org\/10.1177\/14703203211003781","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"3520_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep32103","volume":"6","author":"VC Wu","year":"2016","unstructured":"V.C. Wu, S.M. Wang, C.H. Chang, Y.H. Hu, L.Y. Lin, Y.H. Lin et al. Long term outcome of Aldosteronism after target treatments. Sci. Rep. 6, 32103 (2016). https:\/\/doi.org\/10.1038\/srep32103","journal-title":"Sci. Rep."},{"key":"3520_CR6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u2013916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3520_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/hjh.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"P. Mulatero, S. Monticone, J. Deinum, L. Amar, A. Prejbisz, M.C. Zennaro et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J. Hypertens. 38, 1919\u20131928 (2020). https:\/\/doi.org\/10.1097\/hjh.0000000000002510","journal-title":"J. Hypertens."},{"key":"3520_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"M. Naruse, T. Katabami, H. Shibata, M. Sone, K. Takahashi, A. Tanabe et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 69, 327\u2013359 (2022). https:\/\/doi.org\/10.1507\/endocrj.EJ21-0508","journal-title":"Endocr. J."},{"key":"3520_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.hyp.0000038478.59760.41","volume":"40","author":"P Mulatero","year":"2002","unstructured":"P. Mulatero, F. Rabbia, A. Milan, C. Paglieri, F. Morello, L. Chiandussi et al. Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism. Hypertension 40, 897\u2013902 (2002). https:\/\/doi.org\/10.1161\/01.hyp.0000038478.59760.41","journal-title":"Hypertension"},{"key":"3520_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2265.2002.01613.x","volume":"57","author":"C Seifarth","year":"2002","unstructured":"C. Seifarth, S. Trenkel, H. Schobel, E. Hahn, J. Hensen, Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin. Endocrinol. 57, 457\u201365 (2002). https:\/\/doi.org\/10.1046\/j.1365-2265.2002.01613.x","journal-title":"Clin. Endocrinol."},{"key":"3520_CR11","doi-asserted-by":"publisher","first-page":"061671","DOI":"10.1136\/bmjopen-2022-061671","volume":"12","author":"A Nainani","year":"2022","unstructured":"A. Nainani, J. Yang, S. Peters, G. Russell, \u2018I can\u2019t understand why others don\u2019t screen more\u2019: a qualitative study exploring why Australian general practitioners screen for primary aldosteronism. BMJ Open 12, 061671 (2022). https:\/\/doi.org\/10.1136\/bmjopen-2022-061671","journal-title":"BMJ Open"},{"key":"3520_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11154-011-9163-7","volume":"12","author":"E Fischer","year":"2011","unstructured":"E. Fischer, F. Beuschlein, M. Bidlingmaier, M. Reincke, Commentary on the Endocrine Society Practice Guidelines: consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev. Endocr. Metab. Disord. 12, 43\u20138 (2011). https:\/\/doi.org\/10.1007\/s11154-011-9163-7","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"3520_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/HJH.0b013e3283656b54","volume":"32","author":"PM Jansen","year":"2014","unstructured":"P.M. Jansen, B.J. van den Born, W.J. Frenkel, E.L. de Bruijne, J. Deinum, M.N. Kerstens et al. Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. J. Hypertens. 32, 115\u201326 (2014). https:\/\/doi.org\/10.1097\/HJH.0b013e3283656b54","journal-title":"J. Hypertens."},{"key":"3520_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","volume":"51","author":"G Schwartz","year":"2005","unstructured":"G. Schwartz, S. Turner, Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin. Chem. 51, 386\u201394 (2005). https:\/\/doi.org\/10.1373\/clinchem.2004.041780","journal-title":"Clin. Chem."},{"key":"3520_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.7326\/m22-1619","volume":"175","author":"Y Jing","year":"2022","unstructured":"Y. Jing, J. Hu, R. Luo, Y. Mao, Z. Luo, M. Zhang et al. Prevalence and characteristics of adrenal tumors in an unselected screening population : a cross-sectional study. Ann. Intern. Med. 175, 1383\u20131391 (2022). https:\/\/doi.org\/10.7326\/m22-1619","journal-title":"Ann. Intern. Med."},{"key":"3520_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.eprac.2020.10.016","volume":"27","author":"B Liu","year":"2021","unstructured":"B. Liu, J. Hu, Y. Song, W. He, Q. Cheng, Z. Wang et al. Seated saline suppression test is comparable with captopril challenge test for the diagnosis of primary aldosteronism: a prospective study. Endocr. Pract. 27, 326\u2013333 (2021). https:\/\/doi.org\/10.1016\/j.eprac.2020.10.016","journal-title":"Endocr. Pract."},{"key":"3520_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/hypertensionaha.117.10197","volume":"71","author":"Y Song","year":"2018","unstructured":"Y. Song, S. Yang, W. He, J. Hu, Q. Cheng, Y. Wang et al. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. Hypertension 71, 118\u2013124 (2018). https:\/\/doi.org\/10.1161\/hypertensionaha.117.10197","journal-title":"Hypertension"},{"key":"3520_CR18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","volume":"75","author":"Z Xu","year":"2020","unstructured":"Z. Xu, J. Yang, J. Hu, Y. Song, W. He, T. Luo et al. Primary aldosteronism in patients in China with recently detected hypertension. J. Am. Coll. Cardiol. 75, 1913\u20131922 (2020). https:\/\/doi.org\/10.1016\/j.jacc.2020.02.052","journal-title":"J. Am. Coll. Cardiol."},{"key":"3520_CR19","doi-asserted-by":"publisher","first-page":"101399","DOI":"10.1016\/j.beem.2020.101399","volume":"34","author":"F Buffolo","year":"2020","unstructured":"F. Buffolo, S. Monticone, A. Pecori, J. Pieroni, I. Losano, G. Cavagli\u00e0 et al. The spectrum of low-renin hypertension. Best Pract. Res. Clin. Endocrinol. Metab. 34, 101399 (2020). https:\/\/doi.org\/10.1016\/j.beem.2020.101399","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"3520_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.02898.x","volume":"67","author":"P Mulatero","year":"2007","unstructured":"P. Mulatero, A. Verhovez, F. Morello, F. Veglio, Diagnosis and treatment of low-renin hypertension. Clin. Endocrinol. 67, 324\u201334 (2007). https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02898.x","journal-title":"Clin. Endocrinol."},{"key":"3520_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tem.2005.02.006","volume":"16","author":"J Sealey","year":"2005","unstructured":"J. Sealey, R. Gordon, F. Mantero, Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol. Metab. 16, 86\u201391 (2005). https:\/\/doi.org\/10.1016\/j.tem.2005.02.006","journal-title":"Trends Endocrinol. Metab."},{"key":"3520_CR22","doi-asserted-by":"publisher","unstructured":"M. Thuzar, K. Young, A.H. Ahmed, G. Ward, M. Wolley, Z. Guo, et al. Diagnosis of primary aldosteronism by seated saline suppression test-variability between immunoassay and HPLC-MS\/MS. J. Clin. Endocrinol. Metab. 105 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz150","DOI":"10.1210\/clinem\/dgz150"},{"key":"3520_CR23","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1097\/hjh.0000000000003197","volume":"40","author":"Y Song","year":"2022","unstructured":"Y. Song, J. Yang, H. Shen, E. Ng, P.J. Fuller, Z. Feng et al. Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism. J. Hypertens. 40, 1692\u20131701 (2022). https:\/\/doi.org\/10.1097\/hjh.0000000000003197","journal-title":"J. Hypertens."},{"key":"3520_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/s2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"T.A. Williams, J. Lenders, P. Mulatero, J. Burrello, M. Rottenkolber, C. Adolf et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689\u2013699 (2017). https:\/\/doi.org\/10.1016\/s2213-8587(17)30135-3","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3520_CR25","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1097\/hjh.0000000000001855","volume":"36","author":"H Kobayashi","year":"2018","unstructured":"H. Kobayashi, M. Abe, M. Soma, Y. Takeda, I. Kurihara, H. Itoh et al. Development and validation of subtype prediction scores for the workup of primary aldosteronism. J. Hypertens. 36, 2269\u20132276 (2018). https:\/\/doi.org\/10.1097\/hjh.0000000000001855","journal-title":"J. Hypertens."},{"key":"3520_CR26","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1210\/jc.2010-0225","volume":"95","author":"A Ahmed","year":"2010","unstructured":"A. Ahmed, R. Gordon, P. Taylor, G. Ward, E. Pimenta, M. Stowasser, Effect of atenolol on aldosterone\/renin ratio calculated by both plasma Renin activity and direct Renin concentration in healthy male volunteers. J. Clin. Endocrinol. Metab. 95, 3201\u20136 (2010). https:\/\/doi.org\/10.1210\/jc.2010-0225","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3520_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/cen.12882","volume":"84","author":"G Browne","year":"2016","unstructured":"G. Browne, T. Griffin, P. O\u2019Shea, M. Dennedy, \u03b2-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension. Clin. Endocrinol. 84, 325\u201331 (2016). https:\/\/doi.org\/10.1111\/cen.12882","journal-title":"Clin. Endocrinol."},{"key":"3520_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/hypertensionaha.120.14871","volume":"76","author":"Z Guo","year":"2020","unstructured":"Z. Guo, M. Poglitsch, D. Cowley, O. Domenig, B.C. McWhinney, J. Ungerer, et al. Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin II ratio in patients with primary aldosteronism. Hypertension 76, 488\u2013496 (2020). https:\/\/doi.org\/10.1161\/hypertensionaha.120.14871","journal-title":"Hypertension"},{"key":"3520_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1507\/endocrj.ej13-0060","volume":"60","author":"K Murase","year":"2013","unstructured":"K. Murase, R. Nagaishi, H. Takenoshita, T. Nomiyama, Y. Akehi, T. Yanase, Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr. J. 60, 967\u201376 (2013). https:\/\/doi.org\/10.1507\/endocrj.ej13-0060","journal-title":"Endocr. J."},{"key":"3520_CR30","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1210\/clinem\/dgab290","volume":"106","author":"A Pecori","year":"2021","unstructured":"A. Pecori, F. Buffolo, J. Burrello, G. Mengozzi, F. Rumbolo, V. Avataneo et al. Mineralocorticoid receptor antagonist effect on aldosterone to renin ratio in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 106, 3655 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab290","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3520_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1055\/a-0604-3249","volume":"50","author":"S Pilz","year":"2018","unstructured":"S. Pilz, C. Trummer, N. Verheyen, V. Schwetz, M. Pandis, F. Aberer et al. Mineralocorticoid receptor blockers and aldosterone to renin ratio: a randomized controlled trial and observational data. Horm. Metab. Res. 50, 375\u2013382 (2018). https:\/\/doi.org\/10.1055\/a-0604-3249","journal-title":"Horm. Metab. Res."},{"key":"3520_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.4158\/ep-2020-0277","volume":"26","author":"Y Tezuka","year":"2020","unstructured":"Y. Tezuka, A. Turcu, Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism. Endocr. Pract. 26, 1416\u20131424 (2020). https:\/\/doi.org\/10.4158\/ep-2020-0277","journal-title":"Endocr. Pract."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03520-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T03:34:31Z","timestamp":1705980871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03520-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03520-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3158767\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}